Postoperative complications after combined neoadjuvant treatment of lung cancer

Wyatt C. Fowler, Corey J. Langer, Walter J. Curran, Steven M. Keller

Research output: Contribution to journalArticle

185 Citations (Scopus)

Abstract

Preoperative chemotherapy and radiation administered separately or in combination have been used in the treatment of locally advanced non-small cell lung cancer. To assess the postoperative morbidity and mortality associated with aggressive neoadjuvant therapy, we reviewed the records of 13 patients who underwent resection of locally advanced non-small cell lung cancer after two monthly cycles of infusional 5-fluorouracil, 640 to 800 mg/m2 (days 1 through 5); cisplatin, 20 mg/m2 (days 1 through 5); eloposide, 50 mg/m2 (days 1, 3, and 5); and concomitant radical thoracic irradiation (6,000 cGy) administered in 200-cGy daily fractions. Six patients underwent lobectomy with no mortality, whereas 7 pneumonectomies were associated with three deaths (43%). Culture-negative, diffuse pulmonary infiltrates developed 3 to 6 days after operation in 5 of 7 pneumonectomy patients and in 1 of 6 lobectomy patients. Two patients who had undergone pneumonectomy died of progressive adult respiratory distress syndrome. A third death resulted from a bronchopleural fistula that developed 30 days after pneumonectomy. Morbidity and mortality were not associated with preoperative pulmonary function test results, nutritional status, or intraoperative inspired oxygen fraction (p > 0.05 by χ2 test). Only pneumonectomy correlated with increased morbidity and mortality (p < 0.05 by χ2 test). We conclude that lobectomy may be performed safely after this combination of aggressive chemotherapy and high-dose radiation, but pneumonectomy is associated with unacceptable morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)986-989
Number of pages4
JournalThe Annals of thoracic surgery
Volume55
Issue number4
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Pneumonectomy
Lung Neoplasms
Mortality
Morbidity
Non-Small Cell Lung Carcinoma
Radiation
Respiratory Function Tests
Adult Respiratory Distress Syndrome
Combination Drug Therapy
Nutritional Status
Fluorouracil
Cisplatin
Fistula
Thorax
Oxygen
Drug Therapy
Lung

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Postoperative complications after combined neoadjuvant treatment of lung cancer. / Fowler, Wyatt C.; Langer, Corey J.; Curran, Walter J.; Keller, Steven M.

In: The Annals of thoracic surgery, Vol. 55, No. 4, 1993, p. 986-989.

Research output: Contribution to journalArticle

Fowler, Wyatt C. ; Langer, Corey J. ; Curran, Walter J. ; Keller, Steven M. / Postoperative complications after combined neoadjuvant treatment of lung cancer. In: The Annals of thoracic surgery. 1993 ; Vol. 55, No. 4. pp. 986-989.
@article{d27ff8a886f643ce9995c8142fc8a9d1,
title = "Postoperative complications after combined neoadjuvant treatment of lung cancer",
abstract = "Preoperative chemotherapy and radiation administered separately or in combination have been used in the treatment of locally advanced non-small cell lung cancer. To assess the postoperative morbidity and mortality associated with aggressive neoadjuvant therapy, we reviewed the records of 13 patients who underwent resection of locally advanced non-small cell lung cancer after two monthly cycles of infusional 5-fluorouracil, 640 to 800 mg/m2 (days 1 through 5); cisplatin, 20 mg/m2 (days 1 through 5); eloposide, 50 mg/m2 (days 1, 3, and 5); and concomitant radical thoracic irradiation (6,000 cGy) administered in 200-cGy daily fractions. Six patients underwent lobectomy with no mortality, whereas 7 pneumonectomies were associated with three deaths (43{\%}). Culture-negative, diffuse pulmonary infiltrates developed 3 to 6 days after operation in 5 of 7 pneumonectomy patients and in 1 of 6 lobectomy patients. Two patients who had undergone pneumonectomy died of progressive adult respiratory distress syndrome. A third death resulted from a bronchopleural fistula that developed 30 days after pneumonectomy. Morbidity and mortality were not associated with preoperative pulmonary function test results, nutritional status, or intraoperative inspired oxygen fraction (p > 0.05 by χ2 test). Only pneumonectomy correlated with increased morbidity and mortality (p < 0.05 by χ2 test). We conclude that lobectomy may be performed safely after this combination of aggressive chemotherapy and high-dose radiation, but pneumonectomy is associated with unacceptable morbidity and mortality.",
author = "Fowler, {Wyatt C.} and Langer, {Corey J.} and Curran, {Walter J.} and Keller, {Steven M.}",
year = "1993",
doi = "10.1016/0003-4975(93)90131-Z",
language = "English (US)",
volume = "55",
pages = "986--989",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Postoperative complications after combined neoadjuvant treatment of lung cancer

AU - Fowler, Wyatt C.

AU - Langer, Corey J.

AU - Curran, Walter J.

AU - Keller, Steven M.

PY - 1993

Y1 - 1993

N2 - Preoperative chemotherapy and radiation administered separately or in combination have been used in the treatment of locally advanced non-small cell lung cancer. To assess the postoperative morbidity and mortality associated with aggressive neoadjuvant therapy, we reviewed the records of 13 patients who underwent resection of locally advanced non-small cell lung cancer after two monthly cycles of infusional 5-fluorouracil, 640 to 800 mg/m2 (days 1 through 5); cisplatin, 20 mg/m2 (days 1 through 5); eloposide, 50 mg/m2 (days 1, 3, and 5); and concomitant radical thoracic irradiation (6,000 cGy) administered in 200-cGy daily fractions. Six patients underwent lobectomy with no mortality, whereas 7 pneumonectomies were associated with three deaths (43%). Culture-negative, diffuse pulmonary infiltrates developed 3 to 6 days after operation in 5 of 7 pneumonectomy patients and in 1 of 6 lobectomy patients. Two patients who had undergone pneumonectomy died of progressive adult respiratory distress syndrome. A third death resulted from a bronchopleural fistula that developed 30 days after pneumonectomy. Morbidity and mortality were not associated with preoperative pulmonary function test results, nutritional status, or intraoperative inspired oxygen fraction (p > 0.05 by χ2 test). Only pneumonectomy correlated with increased morbidity and mortality (p < 0.05 by χ2 test). We conclude that lobectomy may be performed safely after this combination of aggressive chemotherapy and high-dose radiation, but pneumonectomy is associated with unacceptable morbidity and mortality.

AB - Preoperative chemotherapy and radiation administered separately or in combination have been used in the treatment of locally advanced non-small cell lung cancer. To assess the postoperative morbidity and mortality associated with aggressive neoadjuvant therapy, we reviewed the records of 13 patients who underwent resection of locally advanced non-small cell lung cancer after two monthly cycles of infusional 5-fluorouracil, 640 to 800 mg/m2 (days 1 through 5); cisplatin, 20 mg/m2 (days 1 through 5); eloposide, 50 mg/m2 (days 1, 3, and 5); and concomitant radical thoracic irradiation (6,000 cGy) administered in 200-cGy daily fractions. Six patients underwent lobectomy with no mortality, whereas 7 pneumonectomies were associated with three deaths (43%). Culture-negative, diffuse pulmonary infiltrates developed 3 to 6 days after operation in 5 of 7 pneumonectomy patients and in 1 of 6 lobectomy patients. Two patients who had undergone pneumonectomy died of progressive adult respiratory distress syndrome. A third death resulted from a bronchopleural fistula that developed 30 days after pneumonectomy. Morbidity and mortality were not associated with preoperative pulmonary function test results, nutritional status, or intraoperative inspired oxygen fraction (p > 0.05 by χ2 test). Only pneumonectomy correlated with increased morbidity and mortality (p < 0.05 by χ2 test). We conclude that lobectomy may be performed safely after this combination of aggressive chemotherapy and high-dose radiation, but pneumonectomy is associated with unacceptable morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=0027158572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027158572&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(93)90131-Z

DO - 10.1016/0003-4975(93)90131-Z

M3 - Article

VL - 55

SP - 986

EP - 989

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 4

ER -